A bad day for Molecular Partners
Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
Lilly and Roche learn from Biogen’s mistakes
As Biogen continues to provide a case study in how not to launch a drug, Lilly and Roche insist the focus must remain on pivotal readouts.
